Gaffey T A, Scheithauer B W, Leech R W, Blick K, Kovacs K, Horvath E, Weaver A L, Lloyd R V, Ebersold M, Laws E R, DeBault L E
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Clin Neuropathol. 2005 Mar-Apr;24(2):56-63.
A clinically, immunohistochemically and ultrastructurally characterized series of 192 pituitary adenomas was analyzed for DNA content by flow cytometry. Results were assessed not only relative to tumor immunotype, size, and invasiveness, but also with frequency of recurrence. Case selection was non-random; males predominated (1.8:1) and the ratio of macro-to-microadenomas was 4.2:1. Female patients were slightly younger and, in all adenoma categories, less often had invasive tumors: PRL (15%/30%), ACTH (17%/44%), LH/FSH (8%/27%) and null cell adenomas (0%/27%). With the exception of prolactin cell adenomas, similar proportions of macroadenomas and invasive tumors in all tumor subtypes were diploid and non-diploid. Prolactin adenomas differed in that tumors of males showed a high rate of non-diploidy (65%); such tumors were predominantly macroadenomas, but only 28% were invasive. Among GH-containing tumors 78% were macroadenomas, 40% were nondiploid, and the frequency of invasive macroadenomas was higher (49%) than in PRL tumors (21%). ACTH adenomas were mainly microadenomas (81%), their rate invasion (29%) and of non-diploidy being low (14%). Among "non-functioning" (LH/FSH, null cell adenomas), LH/FSH-producing tumors were all macroadenomas, but with low rates of invasion (23%) and non-diploidy (9%). Null cell adenomas, nearly all macroadenomas, had similar low invasion rate (21%), but were more often non-diploid (39%). In all adenoma subgroups S-phase fractions were higher in non-diploid adenomas by an overall ratio of 2.1:1. Prolactin adenomas showed the highest (15.2%) and LH/FSH adenomas the lowest (5.6%) mean S-phase fraction. When compared to long-term follow-up, neither this parameter nor ploidy correlated with tumor size or invasiveness. Lastly, long-term follow-up showed ploidy to be an unreliable predictor of tumor persistence or recurrence.
对一组经临床、免疫组化和超微结构特征鉴定的192例垂体腺瘤进行流式细胞术DNA含量分析。不仅根据肿瘤免疫类型、大小和侵袭性评估结果,还根据复发频率进行评估。病例选择并非随机;男性占主导(1.8:1),大腺瘤与微腺瘤的比例为4.2:1。女性患者年龄稍小,在所有腺瘤类型中,侵袭性肿瘤的发生率较低:泌乳素(PRL)腺瘤(15%/30%)、促肾上腺皮质激素(ACTH)腺瘤(17%/44%)、促黄体生成素/促卵泡生成素(LH/FSH)腺瘤(8%/27%)和无功能腺瘤(0%/27%)。除泌乳素细胞腺瘤外,所有肿瘤亚型中大腺瘤和侵袭性肿瘤中二倍体和非二倍体的比例相似。泌乳素腺瘤的不同之处在于男性肿瘤的非二倍体率较高(65%);此类肿瘤主要为大腺瘤,但仅28%具有侵袭性。在含生长激素(GH)的肿瘤中,78%为大腺瘤,40%为非二倍体,侵袭性大腺瘤的发生率(49%)高于泌乳素肿瘤(21%)。ACTH腺瘤主要为微腺瘤(81%),其侵袭率(29%)和非二倍体率较低(14%)。在“无功能”(LH/FSH、无功能腺瘤)腺瘤中,产生LH/FSH的肿瘤均为大腺瘤,但侵袭率(23%)和非二倍体率(9%)较低。无功能腺瘤几乎全是大腺瘤,侵袭率相似(21%),但非二倍体的比例更高(39%)。在所有腺瘤亚组中,非二倍体腺瘤的S期分数总体比例为2.1:1,更高。泌乳素腺瘤的平均S期分数最高(15.2%),LH/FSH腺瘤最低(5.6%)。与长期随访相比,该参数和倍体均与肿瘤大小或侵袭性无关。最后,长期随访显示倍体不是肿瘤持续或复发的可靠预测指标。